首页 | 本学科首页   官方微博 | 高级检索  
检索        

肝癌术后复发患者96例临床分析
引用本文:徐意瑶,杨华瑜,杨晓波,万雪帅,赵海涛,毛一雷,桑新亭,卢欣.肝癌术后复发患者96例临床分析[J].癌症进展,2013,11(5):489-492.
作者姓名:徐意瑶  杨华瑜  杨晓波  万雪帅  赵海涛  毛一雷  桑新亭  卢欣
作者单位:中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730;中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730;中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730;中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730;中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730;中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730;中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730;中国医学科学院北京协和医学院北京协和医院肝脏外科,北京,100730
基金项目:国家自然科学基金面上项目(30970623,91229120);国家国际合作项目(2010DFA31840,2010DFB33720);中华人民共和国教育部2011年度新世纪优秀人才支持计划(NCET-11-0288);北京市自然基金面上项目(5112030)
摘    要:目的探讨如何选择肝癌术后复发患者的治疗方式。方法回顾性分析2007年4月至2012年3月间在我院进行肝癌切除手术后发现复发并接受治疗的96例患者的临床资料。患者分为二次手术组、射频消融(radiofrequency ablation,RFA)组和肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)组,分析治疗方式与临床特征间的关系及对生存的影响。结果各组肝癌术后复发患者的各项临床资料基本无差异,只有肿瘤直径,术中出血量和切缘有显著性差异。但二次手术组患者的无病生存时间和复发后生存时间及总生存时间均高于RFA组和TACE组。结论手术切除在治疗肝癌复发时依然是最佳选择。无法进行二次手术的患者,采取RFA和TACE治疗,复发后生存时间无差异。

关 键 词:肝细胞肝癌  复发  肝切除术  射频消融  肝动脉化疗栓塞

Clinical analysis of 96 postoperative recurrence hepatocellular carcinoma patients
XU Yi-yao,YANG Hua-yu,YANG Xiao-bo,WAN Xue-shuai,ZHAO Hai-tao,MAO Yi-lei,SANG Xin-ting,LU Xin.Clinical analysis of 96 postoperative recurrence hepatocellular carcinoma patients[J].Oncology Progress,2013,11(5):489-492.
Authors:XU Yi-yao  YANG Hua-yu  YANG Xiao-bo  WAN Xue-shuai  ZHAO Hai-tao  MAO Yi-lei  SANG Xin-ting  LU Xin
Institution:Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Abstract:Objective To explore how to choose the suitable treatment method for the hepatocellular carcinoma (HCC) recurrence patients. Method Clinical data of 96 postoperative recurrence HCC patients who received treatment in our hospital from April 2007 to March 2012 were analyzed respectively. Patients were divided into secondary resection group, radiofrequeney ablation (RFA) group and transcatheter arterial chemoembolization (TACE) group. The correlation between treatment methods and other clinieopathological features were analyzed to identify survival differentiations. Result There was no significant difference in various elinicopathological features except tumor diameter, intraoperative blood loss and cut edge. But the disease-free survival time, survival time after recurrence and overall survival time of patients in see- ondary resection group were significantly longer than that of RFA group and TACE group. Conclusion Surgical resection in the treatment for recurrent HCC is still the best choice. There was no difference in survival time after HCC recurrence between the patients treated with RFA and TACE.
Keywords:hepatocellular carcinoma  recurrence  hepatectomy  radiofrcquency ablation  transcatheter arterial chemoembolization
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号